Drug
Asciminib Pediatric Formulation Group
Asciminib Pediatric Formulation Group: highest development phase Phase 1/2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Asciminib Pediatric formulation group NCT04925479 | Phase 1/2 | Myeloid Leukemia, Philadelphia Positive |
Latest
No recent events.
Follow Asciminib Pediatric Formulation Group on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.